Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score‐matched analysis. Issue 1 (27th June 2019)

• Record Type: Journal Article
• Authors: Liao, Jun‐Fang; Zhang, Qun; Du, Xiao‐Jing; Lan, Mei; Liu, Shan; Xia, Yun‐Fei; Cai, Xiu‐Yu; Luo, Wei
• Is Part Of: Cancer communications. Volume 39:Issue 1(2019)
• Page Start: 1
• Page End: 11
• Publication Date: 2019-06-27
• Subjects: Concurrent chemoradiotherapy -- Docetaxel -- Cisplatin -- Nasopharyngeal carcinoma -- Propensity score matching -- Intensity‐modulated radiotherapy -- Overall survival -- Distant metastasis‐free survival -- Locoregional recurrence‐free survival -- Nodal recurrence‐free survival; Cancer -- Periodicals; Neoplasms; Electronic journals; Periodical; Fulltext; Internet Resources; Periodicals; Periodicals; 616.994005
• DOI: 10.1186/s40880-019-0380-x
• Languages: English
• ISSNs: 2523-3548

Abstract

Abstract: Background: Promising efficacy and manageable toxicity of docetaxel‐based concurrent chemoradiotherapy (CCRT) were reported in head and neck cancer. In addition, the effect of CCRT in combination with cisplatin and/or 5‐fluorouracil on both locoregionally advanced and metastatic/recurrent nasopharyngeal carcinoma (NPC) was verified. However, CCRT with docetaxel for locoregionally advanced NPC are not well studied. This study aimed to compare effectiveness and toxicities of CCRT with weekly docetaxel versus tri‐weekly cisplatin for locoregionally advanced NPC. Methods: Clinical data of patients with locoregionally advanced NPC newly diagnosed between January 2010 and December 2014 receiving CCRT with either weekly docetaxel (15 mg/m 2 ) or tri‐weekly cisplatin (80–100 mg/m 2 ) were reviewed. Propensity score matching at a 1:1 ratio was performed to balance baseline characteristics. Adverse events and survival were compared between the two groups. Results: A total of 962 patients were included as the whole cohort, and 448 patients were matched and were regarded as the matched cohort. The median follow‐up duration was 48 months for the whole cohort. The 3‐year nodal recurrence‐free survival rate was significantly increased for patients treated with docetaxel in both the whole (hazard ratio [HR] = 0.37, 95% confidence interval [CI] 0.19–0.72, P = 0.030) and matched cohorts (HR = 0.33, 95% CI 0.14–0.79, P = 0.023). However, no significant differences were observed in overall survival, local recurrence‐free survival, and distant metastasis‐free survival between the two groups in both cohorts. Significantly higher rates of grade 3 radiodermatitis (6.7% vs. 1.8%, P = 0.001), mucositis (74.5% vs. 37.9%, P < 0.001), and leucopenia (2.2% vs. 11.6%, P < 0.001) were observed in the docetaxel group, but any grade of renal injury (1.8% vs. 15.1%, P < 0.001), vomiting (18.8% vs. 88.3%, P < 0.001), and ALT elevation (19.2% vs. 31.3%, P = 0.027) were more common in the cisplatin group. Conclusions: CCRT with weekly low‐dose docetaxel is an effective and tolerable therapeutic regimen for locally advanced NPC. It provides a survival benefit mainly by improving the control of regional lymph node metastases, especially for patients with low pretreatment EBV DNA levels.